Issued on behalf of Avant Technologies Inc.
VANCOUVER – USA News Group News Commentary – Artificial intelligence is rapidly transforming the healthcare sector, with adoption of AI tools accelerating across medical fields. In a recent milestone, researchers at Dartmouth completed the first clinical trial of a generative AI therapy chatbot, reporting significant symptom improvement among participants. Global momentum is also building, as seen in a new collaboration between Cleveland Clinic and UAE-based G42 to advance AI adoption in healthcare. As interest grows, the market is closely watching tech innovators bringing new solutions forward, including from Avant Technologies, Inc. (OTCQB: AVAI), Alphabet, Inc. (NASDAQ: GOOG, GOOGL), Nano-X Imaging Ltd. (NASDAQ: NNOX), RadNet, Inc. (NASDAQ: RDNT), and Microsoft Corporation (NASDAQ: MSFT).
The article continued: Bill Gates recently predicted that AI will soon make medical advice both free and widely available, accelerating major changes in how healthcare is delivered. Meanwhile, private firm Layer Health secured $21 million in new funding to tackle the challenge of scaling AI in healthcare, with backing from Define Ventures, Flare Capital Partners, GV, and MultiCare Capital Partners.
Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City
Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to build momentum in the AI-driven healthcare sector through its joint venture with Ainnova Tech, developers of the Vision AI platform. Today, the two companies announced that Ainnova will sponsor and present at the 2025 Mexico Healthcare Innovation Summit—an international event focused on digital transformation and diagnostics.
Ainnova’s CEO, Vinicio Vargas, will present on preventative healthcare powered by artificial intelligence, highlighting the practical impact of its Vision AI platform on early disease detection, which the company recently began designing the clinical trial protocols for ahead of a pre-submission meeting with the US Food and Drug Administration (FDA).
Vargas’s appearance at the event reinforces a consistent strategy for Avant and Ainnova: increasing visibility across key international markets ahead of major regulatory milestones to come.
It also follows Ainnova's recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas.
As previously mentiond, Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.
Avant and Ainnova jointly control Ai-nova Acquisition Corp. (AAC), which holds global licensing rights to the technology portfolio, including proprietary retinal cameras and algorithms validated on more than 2.3 million clinical data points.
Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Alphabet, Inc. (NASDAQ: GOOG, GOOGL), through its subsidiary Google is expanding its use of AI in healthcare, announcing new Search features to help users find information more easily. The new “What People Suggest” tool uses AI to gather insights from real patient experiences, while expanded knowledge panels now cover thousands of health topics in more countries and languages.
Google also continues to improve its AI Overviews and is developing health-specific tools like MedLM and Vertex AI Search to support clinicians and researchers. Despite past setbacks, the company is doubling down on healthcare with a renewed focus on AI-driven innovation.
Nano-X Imaging Ltd. (NASDAQ: NNOX), an innovative medical imaging technology company, recently announced will present new data from its ADOPT study at four major medical conferences across Europe between March and June 2025. The study used AI to analyze over 37,000 CT scans and identified thousands of undiagnosed vertebral fractures, significantly above the national average.
“These conferences provide an important opportunity to share our growing body of evidence supporting the clinical value of AI in transforming bone health assessment,” said Orit Wimpfheimer, M.D., Chief Medical Officer of Nanox. “With osteoporosis affecting hundreds of millions worldwide, our AI solution is demonstrating the potential to significantly improve early detection rates and enhance patient care pathways.”
Results showed that the AI tool improved early detection of osteoporosis and helped reduce refracture rates, while saving healthcare systems up to £50,000. Nanox's updated AI solution, HealthOST, is FDA-cleared and enhances fracture detection without the need for extra imaging or radiation.
RadNet, Inc. (NASDAQ: RDNT), through its subsidiary DeepHealth has partnered with TeraRecon to create a unified, AI-powered workspace for radiologists by combining diagnostic tools with advanced visualization technology. The collaboration integrates TeraRecon’s cloud imaging platform with DeepHealth’s operating system to streamline radiology workflows and improve diagnostic accuracy.
“[This partnership] equips radiologists with the tools to improve efficiency and reduce variability,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health division.
As imaging demands grow, the platform aims to help radiologists make faster, more consistent decisions under pressure. The partnership also includes plans to expand access to AI-driven cancer screening tools through TeraRecon’s ecosystem.
Microsoft Corporation (NASDAQ: MSFT) recently unveiled Dragon Copilot, an AI-powered clinical workflow assistant designed to reduce the administrative burden on healthcare providers. As physician shortages grow and clinicians face mounting paperwork, Dragon Copilot helps automate documentation, streamline tasks, and support more patient-focused care.
“We weren’t trying to solve the listening and speech problem. We were trying to solve the intelligence problem, and that was the promise of generative AI,” Petro said. He oversees development of Microsoft’s healthcare-specific solutions, such as Nuance Dragon Medical One, Dragon Ambient Experience (DAX) Copilot and Microsoft Cloud for Healthcare.
“Microsoft Dragon Copilot has pushed forward what traditional ambient listening and ambient voice solutions do,” said Jessica Shamash, director of healthcare sales at CDW. “Clinicians can preset their preferences on how they communicate and how they work, and the applications can seamlessly integrate into the health system workflow and her, leveraging AI insights to optimize care plans and communication.”
Built on ambient intelligence, the platform adapts to individual clinician preferences and integrates directly into existing healthcare systems. Microsoft aims to give doctors more face time with patients by moving technology into the background, allowing them to work more efficiently and with less burnout.
“We weren’t trying to solve the listening and speech problem. We were trying to solve the intelligence problem, and that was the promise of generative AI,” said Joe Petro, corporate vice president of health and life science solutions and platforms at Microsoft. “The ambient experience is about pushing technology from in between to actually in the background. It’s the absence of technology in the experience. The technology is really meant to augment the experience. It’s not a pilot. It’s not an autopilot. It’s a co-pilot.”
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
